Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
Future Oncol
; 18(36): 4017-4029, 2022 Nov.
Article
in En
| MEDLINE
| ID: mdl-36622291
ABSTRACT
Aim:
Forty percent of patients with higher-risk myelodysplastic syndromes (HR-MDS) transform to acute myeloid leukemia (AML). Materials &methods:
This retrospective study assessed the impact of HR-MDS transformation to AML on OS in a 6-month landmark analysis and the results were validated using a time-varying analysis.Results:
The rate of AML transformation was 26.9% at 1 year. Patients who transformed to AML had a higher risk of death than patients who did not in the 6-month landmark analysis (HR 1.82; p 0.0072) and time-varying analysis at 1 year (HR 2.85; p < 0.0001). Patients treated with azacitidine and decitabine in first-line therapy had similar results.Conclusion:
HR-MDS transformation to AML is associated with inferior OS in patients with HR-MDS initiating first-line therapy.
Up to 40% of patients with higher-risk myelodysplastic syndromes (HR-MDS) could experience deterioration or progression to acute myeloid leukemia (AML), a type of blood cancer. We conducted a study to assess whether HR-MDS progression to AML had an unfavorable impact on patient life expectancy after initiating treatment for HR-MDS. Our study concluded that patients who experienced progression to AML had a higher chance of dying immediately after their progression to AML than patients who did not. Patients who received azacitidine and decitabine as their first treatment for HR-MDS had similar results.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myelodysplastic Syndromes
/
Leukemia, Myeloid, Acute
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Future Oncol
Year:
2022
Document type:
Article
Affiliation country:
Estados Unidos